Although most of the initial studies in angiogenesis were done on solid tumors, there is now data suggesting the importance of angiogenesis in hematologic malignancies. We estimated bone marrow microvessel density before autologous stem cell transplantation and at the time of response in 13 patients with myeloma (seven complete and six partial responders) using an immunohistochemical stain for factor VIII-related antigen (von Willebrand factor). , P = 0.003. There was no difference in microvessel density at the time of complete or partial response compared to values prior to transplantation. This report confirms that increased angiogenesis is found in myeloma bone marrow prior to transplantation, and suggests that increased angiogenesis persists even after complete response.
Introduction
Most malignant neoplasms are dependent on angiogenesis to sustain proliferation. 1, 2 Angiogenesis is critical for the proliferation and metastasis of tumors and has proven prognostic value in several malignancies. [1] [2] [3] [4] [5] [6] [7] Although many initial studies were done on solid tumors, angiogenesis appears important in hematologic malignancies such as acute leukemia. 8 There is early evidence that bone marrow angiogenesis is correlated with the plasma cell labeling index and is increased in active myeloma. 9, 10 The extent of bone marrow angiogenesis can be assessed using an immunohistochemical stain for factor VIII-related antigen using standard methods. 3, 9, 11 Quantification is accomplished by determining the microvessel density (MVD) and the percentage of unit surface area occupied by microvessels. 3, 9 Such assessments can also be done using computerized image analysis. 6, 11 Since relapse is inevitable in myeloma even after autologous stem cell transplantation, we studied bone marrow MVD in such patients to determine if there was persistent increased angiogenesis at the time of complete response.
Patients and methods

Cohort
We searched our database of 81 consecutive patients who underwent autologous stem cell transplantation for myeloma Correspondence between June 1989 and February 1998, to identify patients who achieved a complete response. Complete response was defined as the disappearance of monoclonal protein from serum and urine by immunoelectrophoresis and immunofixation, as well as eradication of monoclonal plasma cells in the bone marrow based on kappa/lambda staining. Among 26 patients (32%) who had disappearance of the M protein in the serum and urine, we studied seven patients in whom a complete response was confirmed on bone marrow biopsy studies, and in whom paraffin embedded blocks (both pre-transplant and at complete response) were available for factor VIII staining. For comparison, we also studied bone marrow samples from six patients who achieved a partial response with autologous transplantation (defined as a 50% or greater reduction in monoclonal protein). Response bone marrow samples were obtained a median of 6 months post-complete reconstitution of the marrow following stem cell transplantation. Bone marrow samples from five patients with a history of limited stage (stage I) Hodgkin's disease (LSHD) and morphologically normal initial staging bone marrow evaluation were chosen as controls.
The pretransplantation chemotherapy consisted of vincristine, adriamycin and dexamethasone (VAD) for three to four cycles followed by peripheral stem cell harvest. Each cycle of VAD consisted of continuous infusion vincristine (0.4 mg/day × 4 days) and adriamycin (0.9 mg/m 2 /day × 4 days) combined with oral dexamethasone (40 mg/day on days 1-4, 9-12 and 17-20). High-dose cyclophosphamide (3.0-4.5 g/m 2 over 1-2 days) followed by granulocyte colony-stimulating factor (G-CSF) was used as the priming regimen to harvest peripheral blood stem cells in six patients and G-CSF alone was used in six patients. Alkylator-based chemotherapy was used after stem cells were harvested, but prior to transplantation. This consisted of either melphalan and prednisone (MP), or combination chemotherapy with vincristine, carmustine, melphalan, cyclophosphamide and prednisone (VBMCP), administered until relapse, or for 1-2 years in patients who achieved a stable plateau phase. Autologous stem cell transplantation was performed only at the time of refractory or relapsed disease. Transplantation was done following high-dose therapy consisting of melphalan 140 mg/m 2 and total body irradiation (12 Gy). No chemotherapy was administered post-transplantation.
Among the 13 patients with myeloma studied, seven had relapsed disease while on standard dose chemotherapy, three had relapsed while off chemotherapy, two had primary refractory myeloma, that was refractory to both alkylators and VAD, and one patient was in plateau phase of myeloma.
Microvessel staining
Bone marrow biopsy specimens used in this study were prepared from paraffin-embedded blocks. For the 13 patients with myeloma, two bone marrow biopsy samples, one obtained immediately prior to transplant and the other obtained at the time of response were studied. One staging bone marrow biopsy sample obtained at the time of initial diagnosis was studied for the LSHD controls.
Immunohistochemical staining for factor VIII-related antigen (von Willebrand factor) was performed by a labeled streptavidin-biotin peroxidase method on the Ventana ES automated immunohistochemistry stainer (Ventana Medical Systems, Tucson, AZ, USA) using buffers and detection reagents supplied by the manufacturer. Deparaffinized tissue sections were subjected to protease digestion on the instrument with Protease 2 for 12 min prior to immunostaining. The primary antibody (DAKO A0082, Dako, Carpinteria, CA, USA, diluted 1:2000) was incubated with tissue sections for 24 min. The AEC (aminoethyl carbazole) detection kit (Ventana Systems) was used for antigen visualization; sections were counterstained with a light hematoxylin and then coverslipped with Kaiseri's (Mayo Medical Laboratories, Rochester, MN, USA) glycerol jelly. Paraffin sections of well vascularized tonsil were run with each batch to serve as a positive control, and a section stained with non-immune rabbit immunoglobulin was used as a negative control for each sample tested.
Estimation of MVD
Using standard methods, 6, 12 bone marrow MVD was estimated independently by two investigators (SVR and PRG) on all samples using a two-headed microscope. Such a method ensured that microvessel density was estimated on the same field by each investigator. Both investigators were blinded to the diagnosis and clinical details of the samples being studied.
Each slide was first scanned at × 100 magnification to determine three 'hot spots' defined as areas with the maximum number of microvessels. Both investigators examining the slide had to concur on the selection of the hot spots. The slides were then examined at × 400 magnification, using a × 10 ocular and × 40 objective lens. The × 400 field was further defined by an optical grid (reticule) inserted into the ocular lens. The grid has 10 lines on the x and y axis encompassing 100 smaller squares and defined a total area of 0.053 mm 2 . Microvessels were counted within the area defined by the optical grid in each of the three hot spots. Large vessels and vessels in the periosteum or bone were excluded. Areas of staining with no discrete breaks were counted as a single vessel. MVD was estimated by adding the number of vessels in each of the three hot spots and then expressing the result as number of vessels per unit area of cellular tissue (number of vessels per mm 2 ). The area within the optical grid occupied by fat was also estimated. By subtracting the amount of area in each field occupied by fat, we calculated an optimized MVD, 3 which was then expressed as the number of microvessels per mm 2 of cellular area.
Statistical analysis
The two-tailed rank sum test was used for unpaired comparisons. Paired comparisons were done using the two-tailed Wilcoxon signed rank test. Correlation between variables was studied using the Spearman Rank correlation. Time to relapse (or disease progression) was analyzed using the Kaplan-Meier method, 13 and Cox's proportional hazards model. Comparisons between complete and partial responders were done on the post-marrow reconstitution samples, obtained at the time of response. The interval time from marrow reconstitution to sampling was similar between the two groups of patients. No differences in MVD were seen between complete and partial responders at the time of response.
Similar results were seen when optimized MVD was substituted for MVD (Table 1) . We did not find any advantage in substituting optimized MVD for MVD. No significant correlation was seen between MVD (or optimized MVD) and the plasma cell labeling index or bone marrow plasma cell percentage.
There was no correlation between MVD obtained on the response bone marrows and the duration between bone marrow reconstitution and bone marrow sampling, rho = −0.26, P = 0.4. Similar results were obtained when optimized MVD was substituted for MVD, rho = −0.38, P = 0.2.
There was a trend favoring a longer time to relapse with decreasing post-transplant MVD (P = 0.04). However, we were unable to determine a cut-off MVD at which the difference became significant, because of the small sample size of this study. Of interest, two of the three patients in whom the post-transplant MVD decreased by more than 50%, had the longest time to relapse among all patients (Table 1) .
There was agreement between the investigators on the microvessel counts (± three vessels) in more than 95% of readings. For a higher degree of disagreement, vessels were recounted, and a consensus was reached.
Discussion
Despite the use of aggressive approaches such as high-dose therapy and stem cell transplantation, multiple myeloma remains incurable. Patients undergoing stem cell transplantation have higher overall and complete response rates compared to conventional chemotherapy, but the survival gain is modest. Although transplant-related mortality is low in the autologous setting, relapse is inevitable.
In this study, we report a nearly three-fold increase in bone marrow MVD in most patients with myeloma compared to control patients with normal staging bone marrow examination for LSHD (Table 1 ). In fact, MVD was nearly four-fold higher in five patients (38%), suggesting that bone marrow angiogenesis may function as an important factor in the neo- 
Figure 1
Bone marrow biopsy specimens at × 400 magnification, stained with factor VIII-related antigen (von Willebrand Factor) illustrating lack of microvessels in a normal control (a), increased microvessels in myeloma prior to transplant (b, c) as well as myeloma at the time of complete response (d). Arrows point at megakaryocytes that are also stained by factor VIII-related antigen. plastic process. However, not all patients with myeloma had increased MVD and this variability may have prognostic implications.
There was no significant decrease in MVD following treatment, even in the setting of a complete response in most patients. This is unlikely to represent proliferation of microvessels in a post-transplant setting, since these specimens were assessed at the time of response, several months after bone marrow reconstitution. It is not clear if a decrease in MVD by over 50% as seen in two complete responders and one partial responder in our study, may have any prognostic implication, although we did observe a trend to longer time to relapse in two of these patients.
The persistence of angiogenesis after complete response raises several interesting questions and possibilities. Persistent angiogenesis may reflect continued stimulus of microvessels by minimal residual disease not detectable by conventional laboratory methods and may involve potent cytokines, such as vascular endothelial growth factor (VEGF) and acidic and basic fibroblast growth factors. 2, 12 Further, microvascular endothelial cells probably provide growth factors for the residual neoplastic plasma cells that contribute to relapse.
Vacca and colleagues 9, 10, 15 have reported earlier that bone marrow angiogenesis is increased in active myeloma compared to monoclonal gammopathy of undetermined significance (MGUS) or non-active myeloma. They also found that bone marrow angiogenesis, estimated as microvessel surface area, correlated with the plasma cell labeling index rather than bone marrow plasma cell percentage. This suggested that the proliferative activity of neoplastic plasma cells may be related to angiogenesis. Although we did not observe a correlation between MVD and the plasma cell labeling index, this is likely due to the small sample size of our cohort.
We used MVD and optimized MVD to estimate bone marrow angiogenesis. There was no obvious gain in discriminating power detected by eliminating the fatty areas of the marrow from consideration and calculating an optimized MVD. Vacca and colleagues 9 estimated bone marrow angiogenesis by determining the area of cellular marrow occupied by microvessels. Computerized image analysis is another alternative that merits further study. 3 We are planning subsequent studies in a large series of patients to compare the various methods available to measure angiogenesis and determine the most rapid and reliable method for clinical use.
We were unable to compare bone marrow biopsies at initial diagnosis of myeloma to those done prior to transplantation, since bone marrow paraffin blocks from initial diagnosis were not available for most patients in this study. This occurred because we have adopted a strategy of delayed transplantation, and most of our patients are referred from elsewhere for transplantation, often 2 or more years after initial diagnosis of myeloma. However, we are studying bone marrow angiogenesis in a large number of newly diagnosed patients with myeloma, entered on two Eastern Cooperative Oncology Group (ECOG) randomized trials, to assess its prognostic value. We used bone marrow biopsies interpreted as morphologically normal and obtained as part of the initial staging work-up in patients with LSHD, as control samples in this study. Although bone marrow biopsy samples from normal volunteers would have been ideal, we do not have any reason to suspect that the MVD estimates in LSHD patients are lower than normal. Since bone marrow MVD in myeloma patients was significantly higher than in the LSHD controls, there is a possibility that we are actually underestimating the difference between normal and myeloma marrow.
There is a small suggestion based on time to relapse in this study that bone marrow angiogenesis may have prognostic value, but clearly further studies are needed to define the prognostic and biologic significance of angiogenesis in myeloma. However, based on the available evidence, there appears to be some rationale for studies of novel antiangiogenesis agents in myeloma.
